

Jubilant Episcribe LLC
Balance Sheet as at 31 March 2019

		USD	INR (' In Thousands)
	Notes		As at 31 March 2019
ASSETS			
Non-current assets			
Intangible assets under development	1	1,056,440	73,063
Total non-current assets		1,056,440	73,063
Current assets			
Financial assets			
i. Trade receivables	2	1,056,440	73,063
Total current assets		1,056,440	73,063
Total assets		2,112,880	146,126
EQUITY AND LIABILITIES			
Equity			
Equity share capital	3	1,056,440	73,127
Other equity		(2,960)	(269)
Total Equity		1,053,480	72,858
LIABILITIES			
Current liabilities			
Financial liabilities			
i. Trade payables	4	1,059,400	73,268
Total current liabilities		1,059,400	73,268
Total liabilities		1,059,400	73,268
Total equity and liabilities		2,112,880	146,126

Benny Thomas
General Manager Finance

Place: Bangalore
Date: 15th May 2019

Jubilant Episcrite LLC**Statement of Profit and Loss for the year ended 31 March 2019**

		USD	INR (' In Thousands)
	Notes	For the year ended 31 March 2019	
Revenue from operations		-	-
Total income		-	-
Expenses			
Other expenses	5	2,960	209
Total expenses		2,960	209
Loss before tax		(2,960)	(209)
Tax expense			
- Current tax		-	-
- Deferred tax		-	-
Total tax expense		-	-
Loss for the year		(2,960)	(209)
Other comprehensive income			
Items that will be reclassified to profit or loss			
Exchange differences on translation of foreign operations		-	(60)
Other comprehensive loss for the year, net of tax		-	(60)
Total comprehensive loss for the year		(2,960)	(269)

Benny Thomas**General Manager Finance**

Place: Bangalore

Date: 15th May 2019

Statement of changes in Equity for the year ended 31 March 2019

USD

B) Other Equity

USD

Total

Benny Thomas
General Manager Finance

Date: 15th May 2019

Jubilant Episcribe LLC**Statement of changes in Equity for the year ended 31 March 2019****A) Equity share capital**

	INR (' In Thousands)
Balance as at 1 April 2018	-
Additions during the year	73,127
Balance as at 31 March 2019	73,127

B) Other Equity

	INR (' In Thousands)		
	Reserves and Surplus	Other Comprehensive Income	
	Retained earnings	Foreign currency translation reserve	Total
Balances as at 1 April 2018	-	-	-
Loss for the year	(209)	-	(209)
Other comprehensive loss	-	(60)	(60)
Total comprehensive loss for the year	(209)	(60)	(269)
Balances as at 31 March 2019	(209)	(60)	(269)

Benny Thomas
General Manager Finance

Place: Bangalore

Date: 15th May 2019

Jubilant Episcribe LLC**Statement of Cash Flows for the year ended 31 March 2019**

	USD	INR (' In Thousands)
	For the year ended 31 March 2019	
A. Cash flow from operating activities		
Loss before tax	(2,960)	(209)
Operating cash flow before working capital changes	(2,960)	(209)
Increase in trade and other receivables	(1,056,440)	(73,063)
Increase in trade payables, provisions and other liabilities	1,059,400	73,268
Cash used in operations	-	(4)
Income tax and wealth tax paid (net of refund)	-	-
Net cash used in operating activities	-	(4)
B. Cash flow from investing activities		
Net cash generated from / (used in) investing activities	-	-
C. Cash flow arising from financing activities		
Net cash generated from financing activities	-	-
D. Effect of exchange rate changes	-	4
Net decrease in cash and cash equivalents (A+B+C+D)	-	-
Add: cash and cash equivalents at the beginning of year	-	-
Cash and cash equivalents at the end of the year	-	-

Benny Thomas**General Manager Finance**

Place: Bangalore

Date: 15th May 2019

Jubilant Episcrite LLC**Notes to the financial statements for the year ended 31 March 2019****Note 1: Intangible assets under development**

	USD	INR (' In Thousands)
		As at
		31 March 2019
Intangible assets under development	1,056,440	73,063
Total Intangible assets under development	1,056,440	73,063

Note 2: Trade receivables

	USD	INR (' In Thousands)
		As at
		31 March 2019
Unsecured, considered good		
Trade receivables from related parties	1,056,440	73,063
Total trade receivables	1,056,440	73,063

Note 3 : Equity share capital

	USD	INR (' In Thousands)
		As at
		31 March 2019
Issued, subscribed and paid up		
Equity shares	1,056,440	73,127

1) The Company has only one class of shares referred to as equity shares having no par value. Each holder of equity shares is entitled to one vote per share.

2) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company after distribution of all preferential amounts, if any, in proportion to their shareholding. However no such preferential amounts exist currently.

Jubilant Episcrite LLC**Notes to the financial statements for the year ended 31 March 2019**

3) The details of shareholders holding more than 5% shares in the Company:

	As at 31 March 2019	
	No of shares	% holding in the class
Name of the Shareholder		
Jubilant Therapeutics Inc	100	100%

4) The reconciliation of the number of shares outstanding as at beginning and at end of the reporting period

	As at 31 March 2019		
	No of shares	USD	(Rs in thousands)
Numbers of shares at the beginning of the year	-	-	-
Add: Shares issued during the year	100	1,056,440	73,127
Number of shares at the end of the year	100	1,056,440	73,127

5) Equity shares held by holding company/ultimate holding company is set out below:

Particulars	As at
	No of shares
Jubilant Therapeutics Inc	100

Jubilant Episcribe LLC**Notes to the financial statements for the year ended 31 March 2019****Note 4: Trade payables**

	USD	INR (' In Thousands)
		As at
		31 March 2019
Trade payables	2,000	138
Due to related parties	1,057,400	73,130
Total trade payables	1,059,400	73,268

Note 5: Other expenses

	USD	INR (' In Thousands)
		As at
		31 March 2019
Auditors remuneration	2,000	141
Legal and professional fees	960	68
Total other expenses	2,960	209